CAJ | 학술논문

目的：观察低分子肝素治疗晚期肿瘤患者 D-二聚体增高的疗效。方法检测28例晚期肿瘤患者的血凝及血小板结果，并对血栓标志物 D-二聚体增高的患者行低分子肝素皮下注射，每12小时注射1次，治疗7~10 d。检测治疗后相关指标。结果治疗后， D-二聚体水平、纤维蛋白原(Fib)水平低于治疗前，差异有统计学意义(P<0.01)；而患者凝血酶原时间(PT)、活化部分凝血酶时间(APTT)、血小板(PLT)结果与治疗前比较差异无统计学意义(P>0.05)。随访3~20个月，均无血栓疾病发生。结论应用低分子肝素能改善晚期肿瘤患者高凝状态，无出血及其他不良反应，可常规临床应用于晚期肿瘤预防血栓形成。
목적：관찰저분자간소치료만기종류환자 D-이취체증고적료효。방법검측28례만기종류환자적혈응급혈소판결과，병대혈전표지물 D-이취체증고적환자행저분자간소피하주사，매12소시주사1차，치료7~10 d。검측치료후상관지표。결과치료후， D-이취체수평、섬유단백원(Fib)수평저우치료전，차이유통계학의의(P<0.01)；이환자응혈매원시간(PT)、활화부분응혈매시간(APTT)、혈소판(PLT)결과여치료전비교차이무통계학의의(P>0.05)。수방3~20개월，균무혈전질병발생。결론응용저분자간소능개선만기종류환자고응상태，무출혈급기타불량반응，가상규림상응용우만기종류예방혈전형성。
Objective To observe curative effect of low molecular weight heparin in the treatment of advanced tumor patients with increased D-dimer. Methods Blood coagulation and blood platelet were detected in 28 patients with advanced tumor. Those with increased D-dimer as thrombosis marker received subcutaneous injection of low molecular weight heparin once in every 12 h for 7~10 d. Related indexes were detected after treatment. Results After treatment, D-dimer and fibrinogen (Fib) levels were lower than those before treatment, and the difference had statistical significance (P<0.01), while there was no statistically significant difference of prothrombin time (PT), activated partial thromboplastin time (APTT) and platelets (PLT) in patients (P>0.05). Follow-up for 3~20 months showed no occurrence of thrombosis. Conclusion Application of low molecular weight heparin can improve hypercoagulable state in advanced tumor patients, without hemorrhage or other adverse reactions. This method can be used as conventional clinical prevention measure for thrombosis in advanced tumor.